BiotechTube

Furmonertinib + Anlotinib

Phase 2UNKNOWN
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Small-Cell Lung Cancer

Conditions

Non-Small-Cell Lung Cancer

Trial Timeline

Oct 12, 2021 → Nov 30, 2023

NCT ID
NCT04895930

About Furmonertinib + Anlotinib

Furmonertinib + Anlotinib is a phase 2 stage product being developed by Shanghai Allist Pharmaceuticals for Non-Small-Cell Lung Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT04895930. Target conditions include Non-Small-Cell Lung Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04895930Phase 2UNKNOWN

Competing Products

20 competing products in Non-Small-Cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
pemetrexed + erlotinibEli LillyPhase 2
52
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
44
pemetrexed + cisplatinEli LillyPhase 2
52
CetuximabEli LillyPhase 1
33
LY2875358 + ErlotinibEli LillyPhase 2
52
AdjuvantInsight Molecular DiagnosticsPre-clinical
15
Enzastaurin HCLEli LillyPhase 2
52
CAB-AXL-ADC + PD-1 inhibitorBioAtlaPhase 2
44
ALIMTA + CarboplatinEli LillyPhase 2
52
LazertinibYuhanPhase 1/2
41
CS-7017 + ErlotinibDaiichi SankyoPhase 1
33
Datopotamab Deruxtecan (Dato-DXd)Daiichi SankyoPhase 1/2
41
Raludotatug Deruxtecan + Ifinatamab Deruxtecan + Docetetaxel + 5-hydroxytryptamine subtype 3 receptor antagonist + Neurokinin-1 receptor antagonist + CorticosteroidDaiichi SankyoPhase 2
52
Pembrolizumab + Carboplatin + Paclitaxel + Pemetrexed + Vibostolimab + Boserolimab + MK-4830 + MK-0482 + Ifinatamab Deruxtecan (I-DXd) + HER3-DXdDaiichi SankyoPhase 1/2
41
CS-7017 + Carboplatin + PaclitaxelDaiichi SankyoPhase 1
33
Tivantinib + Placebo + ErlotinibDaiichi SankyoPhase 3
77
Gilteritinib + ErlotinibAstellas PharmaPhase 1/2
41
naquotinib + midazolamAstellas PharmaPhase 1
33
Tarceva + carboplatin + paclitaxelAstellas PharmaPhase 2
52
Tarceva (erlotinib HCl, OSI-774 )Astellas PharmaPhase 3
77

Other Products from Shanghai Allist Pharmaceuticals

TKIPre-clinical
20